Basel, January 16, 2026 — Novartis announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ianalumab for the treatment of Sjögren’s disease, a serious and progressive autoimmune disorder with no approved targeted therapies. The designation is supported by positive data from replicate Phase III clinical trials (NEPTUNUS-1 and NEPTUNUS-2), underscoring the therapy’s potential to substantially improve outcomes for patients with significant unmet clinical need.

Science Significance

The Breakthrough Therapy designation highlights the scientific importance of ianalumab’s novel dual mechanism of action, which both depletes B cells and inhibits their activation and survival through BAFF-R blockade. This differentiated biology directly targets key drivers of autoimmune pathology in Sjögren’s disease. In the pivotal Phase III trials, ianalumab demonstrated clinically meaningful reductions in disease activity and patient burden, with a favorable safety profile comparable to placebo. These results position ianalumab as a potential first-in-class targeted immunotherapy capable of addressing the heterogeneous and systemic nature of the disease, which commonly affects salivary glands, fatigue pathways, and multiple organ systems.

Regulatory Significance

From a regulatory perspective, Breakthrough Therapy designation represents one of the FDA’s most impactful development accelerators, reserved for therapies that show substantial improvement over existing options based on clinical evidence. The designation enables intensive FDA guidance, rolling submissions, and expedited review, reducing timelines from late-stage development to potential approval. For ianalumab, this milestone builds on its prior Fast Track designation, reflecting sustained regulatory confidence in the clinical program. Novartis has indicated plans to initiate global regulatory submissions in early 2026, positioning ianalumab for coordinated review across major health authorities.

Business Significance

Strategically, the designation strengthens Novartis’ immunology pipeline and leadership in autoimmune disease innovation. Sjögren’s disease affects an estimated 0.25% of the global population, with approximately half of patients remaining undiagnosed, representing a significant underserved market. If approved, ianalumab could become the first targeted therapy in this indication, establishing a new commercial category. The Breakthrough status also enhances asset value, lifecycle planning, and partnering optionality, while reinforcing Novartis’ long-term investment in high-impact, specialty immunology therapeutics.

Patients’ Significance

For patients, the announcement represents a potential paradigm shift in care. Current management of Sjögren’s disease relies largely on symptomatic treatments, offering limited relief from debilitating features such as dryness, fatigue, pain, and systemic complications, including increased lymphoma risk. The clinical data supporting ianalumab suggest the possibility of a disease-modifying, targeted option that addresses underlying immune dysfunction rather than symptoms alone. Accelerated development increases the likelihood that patients may gain earlier access to an effective therapy, with the potential to meaningfully improve quality of life and long-term outcomes.

Policy Significance

At the policy level, the FDA’s decision reinforces the agency’s commitment to advancing innovation in areas of high unmet need, particularly in autoimmune diseases lacking approved targeted treatments. Breakthrough Therapy designation incentivizes investment in robust late-stage clinical research and supports policies aimed at faster patient access without compromising evidentiary standards. The ianalumab case may also inform future regulatory approaches to complex, heterogeneous autoimmune conditions, where precision immunology strategies are increasingly central to therapeutic progress.

The FDA’s Breakthrough Therapy designation for ianalumab marks a clinically and regulatorily significant milestone in the development of a potential first targeted treatment for Sjögren’s disease. Supported by strong Phase III evidence, the designation accelerates a program that could redefine standards of care in autoimmune medicine. As Novartis prepares for global regulatory submissions in 2026, ianalumab stands out as a leading example of science-driven clinical innovation advancing through expedited regulatory pathways to address profound unmet patient needs.

Source: Novartis press release